Topical calcineurin inhibitors for atopic dermatitis: Review and treatment recommendations

Pediatric Drugs

Volumn 15, Issue 4, 2013, Pages 303-310

  Carr, Warner W ^a  

^a Allergy & Asthma Associates of Southern California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; EMOLLIENT AGENT; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; BURN; CANCER RISK; CUSHING SYNDROME; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENDOCRINE DISEASE; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; GROWTH RETARDATION; HODGKIN DISEASE; HUMAN; HYPOTHALAMIC PITUITARY ADRENAL AXIS SUPPRESSION; INFLAMMATORY DISEASE; LEUKEMIA; LYMPHOMA; MELANOMA; META ANALYSIS (TOPIC); NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; PIGMENT DISORDER; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REBOUND DERMATITIS; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN INFECTION; SKIN MANIFESTATION; STRIA; TELANGIECTASIA; UNITED STATES; VASOCONSTRICTION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; CALCINEURIN; CHILD; DERMATITIS, ATOPIC; DRUG LABELING; EMOLLIENTS; GLUCOCORTICOIDS; HUMANS; NEOPLASMS;

EID: 84880771129     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0013-9     Document Type: Review

References (48)

1. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med. 2005;352(22):2314-24. (Pubitemid 40740555)
2. Valeant Pharmaceuticals North America. Data on file, 2012.
3. Draelos ZD. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Curr Med Res Opin. 2008;24(4):985-94. (Pubitemid 351579155)
4. Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15. (quiz 16-18). (Pubitemid 41832453)
5. Williams HC, Burney PG, Pembroke AC, et al. The UK working party's diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406-16. (Pubitemid 24290228)
6. Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251-1258.e1223.
7. Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73.
8. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361(9352):151-60. (Pubitemid 36092023)
9. Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125-37.
10. ® (Tacrolimus) ointment 0.03 % and ointment 0.1 % (US prescribing information). Deerfield (IL): Fujisawa Healthcare, Inc.; 2000.
11. ® (Pimecrolimus) cream 1 % (US prescribing information). East Hanover (NJ): Novartis Pharmaceuticals Corporation.; 2001.
12. Horii KA, Simon SD, Liu DY, et al. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics. 2007;120(3):e527-34. (Pubitemid 47358264)
13. Stuetz A, Baumann K, Grassberger M, et al. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol. 2006;141(3):199-212. (Pubitemid 44597739)
14. Lin AN. Innovative use of topical calcineurin inhibitors. Dermatol Clin. 2010;28(3):535-45.
15. ® (tacrolimus) capsules and injection (US prescribing information). Deerfield (IL): Astellas Pharma US, Inc.; 2011.
16. Iskedjian M, Piwko C, Shear NH, et al. Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence. Am J Clin Dermatol. 2004;5(4):267-79. (Pubitemid 39127969)
17. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005;330(7490):516. (Pubitemid 40343354)
18. Yan J, Chen SL, Wang XL, et al. Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol. 2008;25(1):117-20. (Pubitemid 351315470)
19. El-Batawy MM, Bosseila MA, Mashaly HM, et al. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2009;54(2):76-87.
20. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21(3):144-56.
21. Svensson A, Chambers C, Ganemo A, et al. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Curr Med Res Opin. 2011;27(7):1395-406.
22. ® (Tacrolimus) ointment 0.03 % and ointment 0.1 % (US prescribing information). Deerfield (IL): Astellas Pharma US, Inc.; 2011.
23. ® (Pimecrolimus) cream 1 % (US prescribing information). East Hanover (NJ): Novartis Pharmaceuticals Corporation.; 2010.
24. Pediatric Advisory Committee presentation from Barbara Hill, Division of Dermatologic and Dental Drug Products, FDA Center for Drug Evaluation and Research. Topical immunosuppressants (calcineurin inhibitors) - animal toxicology, 15 Feb 2005. Available from URL: http://www.fda.gov/ohrms/dockets/ ac/05/slides/2005-4089s2-01-06-Hill.ppt. Accessed 2 Apr 2012.
25. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Protopic NDA 50-777 approval letter, 8 Dec 2000. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2000/50777-Protopic-Approv.pdf. Accessed 23 Jan 2012.
26. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Elidel NDA 21-302 approval letter, 13 Dec 2001. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2001/21-302-ELIDEL-Approv.pdf. Accessed 23 Jan 2012.
27. ® ointment utilization trends following 2006 labeling changes, 17 July 2009. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM204723.pdf. Accessed 2 Apr 2012.
28. Minutes of the Pediatric Advisory Committee meeting. 15 Feb 2005. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4089m1- Minutes.pdf. Accessed 4 Apr 2012.
29. Ring J, Mohrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008;31(3):185-98. (Pubitemid 351311575)
30. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep. 2006;6(4):270-4. (Pubitemid 44056822)
31. Fleischer AB Jr. Black box warning for topical calcineurin inhibitors and the death of common sense. Dermatol Online J. 2006;12(6):2.
32. Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. MedGenMed. 2006;8(4):8.
33. Fonacier L, Spergel J, Charlesworth EN, et al. Report of the topical calcineurin inhibitor task force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2005;115(6):1249-53. (Pubitemid 40824597)
34. American Academy of Dermatology issues statement in response to FDA decision related to two eczema medications (news release). American Academy of Dermatology (AAD); 20 Mar 2005. Available from URL: http://www.thefreelibrary. com/American+Academy+of+Dermatology+Issues+Statement+In+Response+to+FDA. -a0130070456. Accessed 5 Apr 2012.
35. Fast Stats: an interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. http://seer.cancer. gov/faststats. Accessed 8 June 2012.
36. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol. 2011;165(3):465-73.
37. Briefing document from Angelika Manthripragada, Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Calcineurin inhibitor pediatric literature review, 23 Sept 2010. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255139.pdf. Accessed 23 Jan 2012.
38. Briefing document from Angelika Manthripragada, Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Addendum: update on calcineurin inhibitor pediatric literature review, 10 May 2011. Available from URL: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM255140.pdf. Accessed 23 Jan 2012.
39. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007;214(4):289-95. (Pubitemid 46659010)
40. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-16. (Pubitemid 46434650)
41. Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol. 2009;123(5):1111-6.e1113.
42. Hui RL, Lide W, Chan J, et al. Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother. 2009;43(12):1956-63.
43. Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology. 2009;219(1):7-21.
44. Arana A, Wentworth CW, Rivero E, et al. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids and/or topical calcineurin inhibitors (abstract). J Am Acad Dermatol. 2011;64(2 Suppl 1):AB3. (Abstract P203).
45. Arana A, Wentworth CW, Rivero E, et al. Lymphoma among patients with atopic dermatitis treated with topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCIs) (abstract). Pharmacoepidemiol Drug Saf. 2010;19:S12. (Abstract 28).
46. Briefing document from Namita Kothary, Safety Evaluator, Division of Pharmacovigilance I, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Update on Malignancies in Children, 4 Apr 2011. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255145.pdf. Accessed 23 Jan 2012.
47. National Eczema Association (NEA). Topical corticosteroids: myths and facts. http://www.nationaleczema.org/eczema-treatments/topical-corticosteroids. Accessed 2 Apr 2012.
48. American Academy of Dermatology (AAD). Atopic dermatitis: tips for managing. http://www.aad.org/skin-conditions/dermatology-a-to-z/atopic- dermatitis/tips/atopic-dermatitis-tips-for-managing. Accessed 20 Apr 2012.